Taiwan Partners with Czech Institute to Launch €200 Million Medical Aid Program

Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI) has forged a significant partnership with the Czech Health Technology Institute, signing an agreement to initiate a €200 million (approximately US$233.5 million) procurement program aimed at enhancing medical aid in Africa. The formal agreement was established during the Healthcare+ Expo Taiwan in Taipei, marking a pivotal step in international healthcare collaboration.

The contract was signed by IBMI Vice President Yang Pan-chyr and Petr Foit, Chairman of the Czech Health Technology Institute. This collaboration builds on efforts that began in 2023 to facilitate the entry of Taiwanese medical products into European markets. These products include advanced technologies such as handheld ultrasound devices, microplate readers, and electrocardiography systems.

With this new initiative, the partnership aims to supply a variety of medical equipment to support primary healthcare, maternal and child health, and enhance the resilience of hospitals in sub-Saharan Africa. IBMI outlined that the program will focus on sourcing around 20 essential medical items, which include intensive care respiratory devices and vital-sign monitoring equipment, such as fetal heart monitors.

This initiative reflects Taiwan’s ambition to expand its medical technology sector on an international scale. IBMI noted that the program will not only enhance cooperation with multiple countries under the European Union framework but also facilitate entry into emerging markets.

Significant Investment in Healthcare

The Healthcare+ Expo Taiwan, which runs through March 10, 2024, at the Nangang Exhibition Center in Taipei, serves as a platform for networking among global healthcare leaders. During the expo’s opening, President William Lai highlighted the government’s commitment to health innovation, announcing a five-year investment of NT$48.9 billion (approximately US$1.56 billion) to create a “healthy Taiwan.” A key focus of this investment is the promotion of smart healthcare solutions.

President Lai emphasized the importance of adopting the Fast Healthcare Interoperability Resources (FHIR) standard, which aims to facilitate the integration of technology in medical practices. He pointed out that Taiwan not only boasts high-quality healthcare but also has a robust biotechnology industry coupled with a strong technology sector. These elements create a solid foundation for the ongoing development of Taiwan’s medical technology industry.

The partnership with the Czech institute and the ambitious investment plan underscore Taiwan’s proactive approach in establishing itself as a leader in the global healthcare arena, aiming to address vital health needs in regions that require substantial medical support.